Shilpa Medicare Limited
NSE: SHILPAMED · Pharmaceuticals
Snapshot
Unlock Shilpa Medicare Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Shilpa Medicare Limited is a pharmaceutical company specialising in the manufacturing of active pharmaceutical ingredients (APIs), intermediates, and finished formulations, with a strong focus on oncology. The company also provides contract manufacturing services for various dosage forms and maintains a secondary interest in wind power generation.
Business Model
The company generates revenue through the sale of oncology and non-oncology APIs, specialty chemicals, and advanced drug delivery systems. Additionally, it operates a contract development and manufacturing organisation (CDMO) model for global pharmaceutical clients and earns income from renewable energy generation.
Growth Outlook
Growth is expected to be driven by the expansion of its peptide and biotech product portfolio alongside increased capacity in its contract manufacturing division. The company continues to leverage its expertise in complex oncology formulations to capture opportunities in regulated international markets.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent inspections and quality standards imposed by global health authorities like the US FDA.
- Pricing Pressure. Intense competition in the generic API and formulation markets may lead to margin erosion and pricing volatility.
- Geopolitical and Export Risks. As a significant portion of revenue is derived from international markets, the company is susceptible to changes in trade policies and currency fluctuations.
- R&D Failure. The development of new drug delivery systems and biotech products involves high capital expenditure with no guarantee of successful commercialisation.
Start your research today
Unlock AI insights, financials, peers and live data on Shilpa Medicare Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,682 Cr
TTM · consolidated
NET PROFIT
₹297 Cr
TTM · consolidated
EPS
₹15.28
TTM · consolidated
RETURN ON EQUITY
12.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
14.2%
TTM · consolidated
P/E
63.1x
Q1 FY27 · consolidated
EV/EBITDA
40.1x
Q1 FY27 · consolidated
EBITDA MARGIN
28.9%
TTM · consolidated
NET PROFIT MARGIN
21.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Shilpa Medicare LimitedSHILPAMED | ₹18,857 Cr | 63.10 | 40.08 | 27.9% | 28.9% | 12.0% | 14.2% | +14.5% |
Granules India Ltd.GRANULES | ₹21,021 Cr | 31.35 | 16.73 | 24.8% | 22.8% | 15.1% | 20.1% | +65.4% |
Eris Lifesciences Ltd.ERIS | ₹18,314 Cr | 28.11 | 17.93 | 9.7% | 35.5% | 19.7% | 15.5% | -25.1% |
Onesource Specialty Pharma Ltd.ONESOURCE | ₹17,630 Cr | -362.69 | 53.51 | 27.2% | 22.8% | -0.8% | 0.9% | -18.2% |
Cohance Lifesciences Ltd.COHANCE | ₹17,468 Cr | 164.24 | 50.50 | 41.2% | 16.3% | 2.1% | 3.5% | -49.2% |
AstraZenca Pharma India Ltd.ASTRAZEN | ₹17,360 Cr | 102.34 | 65.98 | 31.1% | 10.5% | 20.6% | 25.7% | -23.8% |
As of Q1 FY27
Financials
Shilpa Medicare Limited
NSE: SHILPAMED · Pharmaceuticals
Snapshot
Unlock Shilpa Medicare Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Shilpa Medicare Limited is a pharmaceutical company specialising in the manufacturing of active pharmaceutical ingredients (APIs), intermediates, and finished formulations, with a strong focus on oncology. The company also provides contract manufacturing services for various dosage forms and maintains a secondary interest in wind power generation.
Business Model
The company generates revenue through the sale of oncology and non-oncology APIs, specialty chemicals, and advanced drug delivery systems. Additionally, it operates a contract development and manufacturing organisation (CDMO) model for global pharmaceutical clients and earns income from renewable energy generation.
Growth Outlook
Growth is expected to be driven by the expansion of its peptide and biotech product portfolio alongside increased capacity in its contract manufacturing division. The company continues to leverage its expertise in complex oncology formulations to capture opportunities in regulated international markets.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent inspections and quality standards imposed by global health authorities like the US FDA.
- Pricing Pressure. Intense competition in the generic API and formulation markets may lead to margin erosion and pricing volatility.
- Geopolitical and Export Risks. As a significant portion of revenue is derived from international markets, the company is susceptible to changes in trade policies and currency fluctuations.
- R&D Failure. The development of new drug delivery systems and biotech products involves high capital expenditure with no guarantee of successful commercialisation.
Start your research today
Unlock AI insights, financials, peers and live data on Shilpa Medicare Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,682 Cr
TTM · consolidated
NET PROFIT
₹297 Cr
TTM · consolidated
EPS
₹15.28
TTM · consolidated
RETURN ON EQUITY
12.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
14.2%
TTM · consolidated
P/E
63.1x
Q1 FY27 · consolidated
EV/EBITDA
40.1x
Q1 FY27 · consolidated
EBITDA MARGIN
28.9%
TTM · consolidated
NET PROFIT MARGIN
21.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27